The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Relmacabtagene autoleucel receives China NMPA supplementary biological application approval for R/R MCL
On August 27, 2024, it was announced that the China National Medical Products Administration (NMPA) approved a supplementary biological application for relmacabtagene autoleucel (relma-cel), a CD20-directed chimeric antigen receptor T-cell therapy, for the treatment of adult patients with relapsed/refractory mantle cell lymphoma after ≥2 prior lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. This approval was based on positive results from the pivotal trial conducted in China.
Key data from the pivotal trial
Among the evaluable patients with mantle cell lymphoma (n = 59):
- Best objective response rate was 81.36%
- Best complete response rate was 67.80%
- Grade ≥3 cytokine release syndrome and Grade ≥3 neurotoxicity each occurred in 6.8%
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
